Altimmune Stock Performance


USD 10.10  0.25  2.42%   

The firm shows a Beta (market volatility) of 1.7689, which signifies a somewhat significant risk relative to the market. Let's try to break down what Altimmune's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Altimmune will likely underperform. Even though it is essential to pay attention to Altimmune historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Altimmune exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Altimmune has an expected return of -0.91%. Please be advised to confirm Altimmune value at risk, as well as the relationship between the skewness and day median price to decide if Altimmune performance from the past will be repeated at some point in the near future.
Altimmune Performance
0 of 100
Over the last 90 days Altimmune has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in January 2023. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more

Altimmune Price Channel

Begin Period Cash Flow115951981.00
Total Cashflows From Investing Activities87523127.00

Altimmune Relative Risk vs. Return Landscape

If you would invest  2,046  in Altimmune on September 11, 2022 and sell it today you would lose (1,036)  from holding Altimmune or give up 50.64% of portfolio value over 90 days. Altimmune is generating negative expected returns assuming volatility of 6.0128% on return distribution over 90 days investment horizon. In other words, 52% of stocks are less volatile than Altimmune, and above 99% of all equities are expected to generate higher returns over the next 90 days.
  Daily Expected Return (%)  
       Risk (%)  
Considering the 90-day investment horizon Altimmune is expected to under-perform the market. In addition to that, the company is 4.05 times more volatile than its market benchmark. It trades about -0.15 of its total potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.01 per unit of volatility.

Altimmune Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Altimmune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Altimmune, and traders can use it to determine the average amount a Altimmune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1507

Good Returns
Average Returns
Small Returns
Negative ReturnsALT
Estimated Market Risk
  actual daily
 52 %
of total potential
Expected Return
  actual daily
 0 %
of total potential
Risk-Adjusted Return
  actual daily
 0 %
of total potential
Based on monthly moving average Altimmune is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Altimmune by adding it to a well-diversified portfolio.

About Altimmune Performance

To evaluate Altimmune Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Altimmune generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Altimmune Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Altimmune market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Altimmune's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-57.9 K-62.5 K
Return on Investment(45.61) (49.21) 
Return on Average Assets(41.85) (45.15) 
Return on Average Equity(45.69) (46.89) 
Return on Invested Capital(2.15) (2.32) 
Return on Sales(22.01) (22.59) 

Things to note about Altimmune

Checking the ongoing alerts about Altimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Altimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Altimmune Alerts

Equity Alerts and Improvement Suggestions

Altimmune generated a negative expected return over the last 90 days
Altimmune has high historical volatility and very poor performance
The company reported the last year's revenue of 4.41 K. Reported Net Loss for the year was (97.09 K) with loss before taxes, overhead, and interest of (71.09 M).
Altimmune has about 184.76 M in cash with (78.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Altimmune has a frail financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from Altimmune Weight Loss Data Signals A Costly Confusion - Seeking Alpha
Please continue to Trending Equities. You can also try Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.